BRPI0512869A - composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente - Google Patents

composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente

Info

Publication number
BRPI0512869A
BRPI0512869A BRPI0512869-2A BRPI0512869A BRPI0512869A BR PI0512869 A BRPI0512869 A BR PI0512869A BR PI0512869 A BRPI0512869 A BR PI0512869A BR PI0512869 A BRPI0512869 A BR PI0512869A
Authority
BR
Brazil
Prior art keywords
compounds
disorder
disease
patient
treating
Prior art date
Application number
BRPI0512869-2A
Other languages
English (en)
Inventor
Youssef L Bennani
Bayard Huck
Michael J Robarge
Original Assignee
Athersys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc filed Critical Athersys Inc
Publication of BRPI0512869A publication Critical patent/BRPI0512869A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODO DE TRATAMENTO DE UMA DOENçA, DISTúRBIO E/OU CONDIçãO EM UM PACIENTE A presente invenção refere-se geralmente a uma série de compostos, a composições farmacêuticas contendo os compostos, e ao uso dos compostos e composições como agentes terapêuticos. Mais especificamente, os compostos da presente invenção são compostos indenopirrol tricíclicos. Estes compostos são ligandos de receptor de serotonina (5-HT) e são utilizáveis no tratamento de doenças, distúrbios, e condições, em que a modulação da atividade dos receptores de serotonina (5-HT) é desejada (por exemplo ansiedade, depressão e obesidade).
BRPI0512869-2A 2004-07-29 2005-07-26 composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente BRPI0512869A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59204704P 2004-07-29 2004-07-29
PCT/US2005/026415 WO2007081299A2 (en) 2004-07-29 2005-07-26 Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0512869A true BRPI0512869A (pt) 2008-04-08

Family

ID=37075566

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512869-2A BRPI0512869A (pt) 2004-07-29 2005-07-26 composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente

Country Status (16)

Country Link
US (5) US20060025601A1 (pt)
EP (1) EP1841738A4 (pt)
JP (1) JP4990164B2 (pt)
KR (2) KR20130047765A (pt)
CN (1) CN101516372A (pt)
AR (1) AR050274A1 (pt)
AU (1) AU2005333518B2 (pt)
BR (1) BRPI0512869A (pt)
CA (1) CA2603249C (pt)
IL (1) IL180977A (pt)
NO (1) NO20071102L (pt)
NZ (1) NZ552806A (pt)
RU (1) RU2007107494A (pt)
TW (1) TWI377195B (pt)
WO (1) WO2007081299A2 (pt)
ZA (1) ZA200700684B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007107494A (ru) * 2004-07-29 2008-09-10 Эсерсис, Инк. (US) Трициклические производные инденопиррола как модуляторы серотининовых рецепторов, фармацевтическая композиция на их основе и способ лечения заболеваний, растройств и/или патологических состояний, связанных с необходимостью модуляции функции 5-нт2с рецепторов
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
KR101126383B1 (ko) 2007-02-07 2012-04-12 교와 핫꼬 기린 가부시키가이샤 3환계 화합물
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP3081213B1 (en) 2008-08-06 2020-04-01 Kyowa Kirin Co., Ltd. Tricyclic compound
TW201041851A (en) 2009-03-10 2010-12-01 Organon Nv Tricyclic heterocyclic derivatives
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN106380440B (zh) * 2016-08-30 2019-02-01 华东师范大学 一种茚酮并吡咯类衍生物及其合成方法和应用
CN106631989B (zh) * 2016-11-26 2019-07-16 威海迪素制药有限公司 一种盐酸多奈哌齐有关物质e的制备方法
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3576334D1 (de) * 1984-07-25 1990-04-12 Abbott Lab 1,2,3,3a,8,8a-hexahydro-indeno-(1,2-c)pyrrde.
US4622405A (en) * 1984-07-25 1986-11-11 Abbott Laboratories 1,2,3,3a,8,8a-hexahydro-indeno[1,2-c]pyrroles useful in the treatment of hypertension
ATE139230T1 (de) * 1988-12-15 1996-06-15 Abbott Lab 5-ht-selektive mittel
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
US5244888A (en) 1989-11-17 1993-09-14 Abbott Laboratories 5-HT selective agents
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US7351711B2 (en) * 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
RU2007107494A (ru) * 2004-07-29 2008-09-10 Эсерсис, Инк. (US) Трициклические производные инденопиррола как модуляторы серотининовых рецепторов, фармацевтическая композиция на их основе и способ лечения заболеваний, растройств и/или патологических состояний, связанных с необходимостью модуляции функции 5-нт2с рецепторов

Also Published As

Publication number Publication date
CN101516372A (zh) 2009-08-26
KR101257233B1 (ko) 2013-04-29
JP2008508365A (ja) 2008-03-21
US20090239925A1 (en) 2009-09-24
IL180977A0 (en) 2009-02-11
JP4990164B2 (ja) 2012-08-01
WO2007081299A3 (en) 2007-09-20
US8716324B2 (en) 2014-05-06
IL180977A (en) 2012-08-30
EP1841738A4 (en) 2010-06-02
KR20080025657A (ko) 2008-03-21
NZ552806A (en) 2009-09-25
US20110172283A1 (en) 2011-07-14
CA2603249C (en) 2014-01-21
CA2603249A1 (en) 2007-07-19
RU2007107494A (ru) 2008-09-10
KR20130047765A (ko) 2013-05-08
US9096520B2 (en) 2015-08-04
ZA200700684B (en) 2008-10-29
EP1841738A2 (en) 2007-10-10
TW200619196A (en) 2006-06-16
NO20071102L (no) 2007-04-20
AR050274A1 (es) 2006-10-11
US7935830B2 (en) 2011-05-03
WO2007081299A2 (en) 2007-07-19
US20060025601A1 (en) 2006-02-02
AU2005333518B2 (en) 2010-12-02
TWI377195B (en) 2012-11-21
US20140206739A1 (en) 2014-07-24
US8232311B2 (en) 2012-07-31
US20120252859A1 (en) 2012-10-04
AU2005333518A1 (en) 2007-02-22
AU2005333518A8 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
BRPI0512869A (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente
BRPI0512742A (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente em que modulação de uma função 5-ht2c é desejada
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
BRPI0518011A (pt) uso de tetraidrocanabidivarina, métodos para o tratamento de uma doença ou condição e para cosmeticamente beneficiar a perda de peso, e, uso de um antagonista do receptor de canabinóide neutro
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BRPI0712976A2 (pt) uso de 2-aminotetralinas substituÍdas para a fabricaÇço de um medicamento para a prevenÇço, alÍvio e/ou tratamento de vÁrios tipos de dor
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
UY28945A1 (es) Derivados de pirrolopiridina
BRPI0507198A (pt) derivados de bisariluréia
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
TW200621787A (en) Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
BRPI0517740A (pt) compostos n-sulfonilaminobenzil-2fenóxi acetamida substituìda
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR112013003847A8 (pt) métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
BR0215801A (pt) Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]